title: Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus.
authors.forename: M D
authors.initials: MD
authors.lastname: de Kruif
authors.forename: M
authors.initials: M
authors.lastname: Limper
authors.forename: H R
authors.initials: HR
authors.lastname: Hansen
authors.forename: J
authors.initials: J
authors.lastname: de Ruiter
authors.forename: C A
authors.initials: CA
authors.lastname: Spek
authors.forename: E C M
authors.initials: EC
authors.lastname: van Gorp
authors.forename: I J
authors.initials: IJ
authors.lastname: ten Berge
authors.forename: A T
authors.initials: AT
authors.lastname: Rowshani
authors.forename: H
authors.initials: H
authors.lastname: ten Cate
authors.forename: E W
authors.initials: EW
authors.lastname: Meesters
mesh_terms: D002097:C-Reactive Protein / Q000378:metabolism; D018592:Cross-Over Studies; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein